Thus, the utilization of low-digestible and/or low-absorbable materials, such as flavonoids and slowly digestible peptides, is a promising and safe strategy for the treatment and prevention of metabolic diseases, including obesity and glucose intolerance, by increasing GLP-1 secretion. Here, GLP1R is linked to metabolic disease.